SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.
On June 5, 2017, Sonoma Pharmaceuticals, Inc. issued a press
release announcing financial results for its fiscal quarter and
year ended March 31, 2017. The full text of the press release is
furnished as Exhibit 99.1. The information furnished therein
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liability of that Section.
This report contains forward-looking statements. Forward-looking
statements include, but are not limited to, statements that
express the Companys intentions, beliefs, expectations,
strategies, predictions or any other statements related to its
future activities or future events or conditions. These
statements are based on current expectations, estimates and
projections about the Companys business based, in part, on
assumptions made by management. These statements are not
guarantees of future performances and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed or forecasted in the forward-looking statements
due to numerous factors, including those risks discussed in the
Companys Annual Report on Form 10-K and in other documents that
it files from time to time with the SEC. Any forward-looking
statements speak only as of the date on which they are made, and
the Company does not undertake any obligation to update any
forward-looking statement to reflect events or circumstances
after the date of this report, except as required by law.
Item 9.01Financial Statements and Exhibits.
Press Release issued by Sonoma Pharmaceuticals, Inc., dated
June 5, 2017.
About SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA)
Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.